SOD1 and amyotrophic lateral sclerosis: Overall, these results have implications for understanding the role of SOD1 toxic gain of function in ALS, which is particularly relevant in the context of therapeutics which reduce mutant SOD1 levels in ALS patient CNS, such as Tofersen57,58.